Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice.

AUTOR(ES)

Lyman, C A

RESUMO

UK-49,858, a new antifungal triazole derivative, was compared with amphotericin B in the treatment of pulmonary infections by Blastomyces dermatitidis in male BALB/cByJ mice. Administration of UK-49,858 in daily doses of 25 or 50 mg/kg for 21 days gave 30 and 100% survival rates, respectively. These results compared with 100% mortality in infected controls and 100% survival among mice treated with amphotericin B. UK-49,858 did not eradicate the fungus from the lungs of surviving animals, while amphotericin B effected sterilization of the lungs in 66% of the survivors.

Documentos Relacionados

• Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.
• Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.
• Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.
• Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum.
• Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.